Results 21 to 30 of about 839,337 (241)

Safety and Immunogenicity of the mRNA-1273 Coronavirus Disease 2019 Vaccine in Solid Organ Transplant Recipients. [PDF]

J Infect Dis
Figueroa AL, Azzi JR, Eghtesad B, Priddy F, Stolman D, Siangphoe U, Leony Lasso I, de Windt E, Girard B, Zhou H, Miller JM, Das R.   +11 more
europepmc   +3 more sources

Determinants of protective humoral response to mRNA-1273 and BNT162b2 vaccines in peritoneal dialysis patients: a prospective cohort study. [PDF]

BMC Nephrol
Dimitrov Y, Krummel T, Chantrel F, Heibel F, Kribs M, Hannedouche T.   +5 more
europepmc   +3 more sources

Antibody Response in Immunocompromised Patients After the Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine BNT162b2 or mRNA-1273: A Randomized Controlled Trial [PDF]

, 2022
BACKGROUND BNT162b2 by Pfizer-BioNTech and mRNA-1273 by Moderna are the most commonly used vaccines to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections.
Abela, Irene A, Amico, Patrizia, Audigé, Annette, Braun, Dominique L, Briel, Matthias, Bucher, Heiner C, Chammartin, Frédérique, Eichenberger, Anna L, Günthard, Huldrych F, Hasse, Barbara, Koller, Michael T, Kusejko, Katharina, Mueller, Nicolas J, Müller, Thomas F, Rauch, Andri, Schuurmans, Macé M, Speich, Benjamin, Stoeckle, Marcel P, Tamm, Michael, Trkola, Alexandra   +19 more
core   +6 more sources

Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Older Adults: Systematic Literature Review and Meta-Analysis Using the GRADE Framework [PDF]

Infectious Disease and Therapy
INTRODUCTION:The mRNA vaccines mRNA-1273 and BNT162b2 demonstrated high efficacy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in phase 3 clinical trials, including among older adults.
Bausch-Jurken, MT, Beck, E, Green, N, Haeussler, K, Kavikondala, S, Malmenäs, M, Mishra, NK, Nassim, M, Sharma, P, Van de Velde, N, Wang, X   +10 more
core   +2 more sources

Immunogenicity and safety of heterologous mRNA-1273/MVC-COV1901 vaccination versus homologous mRNA1273 vaccination: A randomized, double-blind controlled study

Journal of the Formosan Medical Association, 2023
Background/Purpose: MVC-COV1901 is a protein vaccine based on the same SARS-CoV-2 strain used in mRNA vaccine mRNA-1273. Data are lacking on immunogenicity and safety of MVC-COV1901 as heterologous boost for people already received one dose of mRNA-1273.
Szu-Ting Huang, Yu-Shan Huang, Wang-Da Liu, Sung-Ching Pan, Hsin-Yun Sun, Chia-En Lien, Charles Chen, Szu-Min Hsieh   +7 more
doaj   +1 more source

Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants

Nature Medicine, 2022
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron (B.1.1.529) variant is highly transmissible with potential immune escape. We conducted a test-negative case–control study to evaluate mRNA-1273 vaccine effectiveness (VE) against ...
H. Tseng, B. Ackerson, Yi Luo, L. Sy, C. Talarico, Yun Tian, K. Bruxvoort, J. Tubert, A. Florea, J. Ku, Gina S. Lee, S. Choi, H. Takhar, Michael Aragones, L. Qian   +14 more
semanticscholar   +1 more source

Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial

Science, 2021
Description Antibody levels predict vaccine efficacy Symptomatic COVID-19 infection can be prevented by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines.
P. Gilbert, D. Montefiori, A. McDermott, Y. Fong, D. Benkeser, Wei-zhi Deng, Honghong Zhou, Christopher R. Houchens, Karen Martins, L. Jayashankar, F. Castellino, B. Flach, Bob C. Lin, S. O'connell, C. McDanal, Amanda Eaton, M. Sarzotti-Kelsoe, Yiwen Lu, Chenchen Yu, Bhavesh Borate, Lars van der Laan, N. Hejazi, C. Huynh, Jacqueline Miller, Hana M. El Sahly, L. Baden, Mira Baron, Luis I. De La Cruz, C. Gay, Spyros A. Kalams, Colleen F. Kelley, M. Andrasik, J. Kublin, L. Corey, K. Neuzil, Lindsay N. Carpp, R. Pajon, D. Follmann, R. Donis, R. Koup   +39 more
semanticscholar   +1 more source

Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19

New England Journal of Medicine, 2021
* Interim results from a phase 3 trial of the Moderna mRNA-1273 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine indicated 94% efficacy in preventing coronavirus disease 2019 (Covid-19).
N. Doria-Rose, M. Suthar, M. Makowski, S. O'connell, A. McDermott, B. Flach, J. Ledgerwood, J. Mascola, B. Graham, Bob C. Lin, S. O'Dell, S. Schmidt, A. Widge, V. Edara, E. Anderson, L. Lai, K. Floyd, N. Rouphael, V. Zarnitsyna, P. Roberts, M. Makhene, Wendy L. Buchanan, C. Luke, J. Beigel, L. Jackson, K. Neuzil, H. Bennett, B. Leav, J. Albert, Pratap Kunwar   +29 more
semanticscholar   +1 more source

Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19

Nature Communications, 2023
We previously presented day 29 interim safety and immunogenicity results from a phase 2/3 study (NCT04927065) comparing the Omicron-BA.1-containing bivalent vaccine mRNA-1273.214 (50-µg) to the 50-µg mRNA-1273 booster in adults who previously received ...
Spyros Chalkias, Charles Harper, Keith Vrbicky, Stephen R. Walsh, Brandon Essink, Adam Brosz, Nichole McGhee, Joanne E. Tomassini, Xing Chen, Ying Chang, Andrea Sutherland, David C. Montefiori, Bethany Girard, Darin K. Edwards, Jing Feng, Honghong Zhou, Lindsey R. Baden, Jacqueline M. Miller, Rituparna Das   +18 more
doaj   +1 more source

Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination

Journal of the Formosan Medical Association, 2022
Background/Purpose: Efficacy and safety data of heterologous prime-boost vaccination against SARS-CoV-2 remains limited. Methods: We recruited adult volunteers for homologous or heterologous prime-boost vaccinations with adenoviral (ChAdOx1, AstraZeneca)
Wang-Huei Sheng, Sui-Yuan Chang, Pin-Hung Lin, Ming-Ju Hsieh, Hao-Hsiang Chang, Chien-Yu Cheng, Hung-Chih Yang, Ching-Fu Pan, Si-Man Ieong, Tai-Ling Chao, Jang-Pin Chen, Shu-Hsing Cheng, Shan-Chwen Chang   +12 more
doaj   +1 more source